Mazdutide cut body weight 14% at 48 weeks in a Chinese phase 3 trial

How much weight does mazdutide produce?

Mazdutide 6 mg produced 14.01% mean body weight loss at 48 weeks versus 0.30% with placebo (p<0.001) in a phase 3 trial of 610 Chinese adults with obesity or overweight ^[1].

Nearly half of participants (49.5%) lost at least 15% of body weight, and every prespecified cardiometabolic measure improved ^[1]. That phase 3 trial is the largest published mazdutide trial, and its 48 weeks are the longest published follow-up.

How is mazdutide different from tirzepatide?

Mazdutide activates the GLP-1 and glucagon receptors, while tirzepatide pairs GLP-1 with GIP, so the two "dual agonists" differ at the second receptor.

Mazdutide is a synthetic analogue of oxyntomodulin, a native human gut peptide that activates both the GLP-1 receptor and the glucagon receptor. That pairing is the entire pharmacological identity of the molecule. Forum shorthand flattens "dual agonist" into one category that also includes tirzepatide, and the tirzepatide trial record belongs to a different receptor pairing.

GIP co-agonism amplifies insulin secretion and fat-cell handling without directly touching the liver's glucose output. Glucagon receptor agonism does something structurally different: it signals the liver to release stored glucose, the opposite of what someone lowering blood sugar wants. The history of oxyntomodulin itself is covered separately.

What does mazdutide's glucagon component trade off?

Mazdutide's glucagon activity raises hepatic glucose output, which works against blood sugar lowering, in exchange for a proposed rise in resting energy expenditure and lipid oxidation.

The energy-expenditure and lipid-oxidation mechanisms come from the broader oxyntomodulin and glucagon-receptor pharmacology literature. The mazdutide trials did not demonstrate them peptide by peptide.

The GLP-1 side of mazdutide does the familiar work: appetite suppression, slowed gastric emptying, and improved insulin sensitivity. The trials show consistent weight loss alongside meaningful HbA1c improvement, which suggests the GLP-1 component's glucose-lowering effect outweighs the glucagon component's glucose-raising pull at the doses tested. That balance is a designed outcome of dose-finding, not a mechanism-free bonus.

What did the phase 2 mazdutide trials show?

Two phase 2 trials, one in type 2 diabetes and one in obesity, showed weight and metabolic improvements over placebo ^[2]⁠^[3], and mazdutide beat dulaglutide head-to-head ^[2].

In 250 participants with type 2 diabetes, 20 weeks of mazdutide at 3 to 6 mg cut HbA1c by 1.41 to 1.67 percentage points, versus 0.03 with placebo (p<0.0001 across doses). Weight loss reached up to 7.1%, versus 1.4% on placebo. Mazdutide also outperformed open-label dulaglutide 1.5 mg, an active GLP-1-only comparator, on both HbA1c and weight ^[2].

In 248 overweight or obese adults, 24 weeks of mazdutide 6 mg produced an 11.3% mean weight reduction, against a 1.0% change with placebo (treatment difference -12.3%, p<0.0001). Waist circumference, blood pressure, lipids, and liver enzymes improved in a dose-dependent pattern ^[3].

What does the mazdutide meta-analysis show?

A meta-analysis pooling 7 RCTs and 680 participants found that mazdutide reduced body weight by a mean of 6.22 percentage points versus placebo (95% CI 4.41 to 8.02%) ^[4].

Systolic blood pressure, total cholesterol, LDL, and triglycerides fell consistently. Effects were larger in non-diabetic participants and with longer treatment duration, and the analysis flagged substantial heterogeneity (I² = 90%) across the pooled trials ^[4].

That heterogeneity makes the pooled 6.22-point weight difference a central estimate across varying trial designs and durations ^[4]. It is not a number that transfers cleanly to any individual dosing scenario.

How strong is the evidence for mazdutide?

Mazdutide's evidence earns grade A, because it rests on multiple double-blind, placebo- or active-controlled RCTs, but it is narrow in population and duration.

The trials report real endpoints, not surrogate biomarkers or open-label extension data dressed up as pivotal results. Read together, they form a strong signal: three separate RCTs, dose-response relationships, an active comparator beaten head-to-head, and biomarker improvements that track the proposed mechanism.

The evidence is not yet broad or long. Every trial enrolled Chinese adults specifically, the longest published follow-up is 48 weeks, and neither the trials nor the meta-analysis report hard cardiovascular outcomes, such as MACE or mortality, as endpoints.

What mazdutide doses were tested?

Mazdutide's phase 2 programs tested 3, 4.5, and 6 mg once weekly, and the 6 mg dose consistently produced the largest weight and metabolic effects ^[2]⁠^[3].

The dose-ranging exists because glucagon receptor engagement needs enough GLP-1 activity riding alongside it to keep glycemic control net-positive. For that reason, mazdutide's titration cannot be safely assumed to mirror tirzepatide's. The two molecules manage different receptor-pairing math, and a schedule built for GIP co-agonism has no established relevance to a glucagon co-agonist's dose-response curve.

None of the published trials details a week-by-week titration protocol at the granularity forum dosing charts imply. The public record holds the dose tiers tested and their outcomes, not a validated escalation schedule for outside use.

What side effects does mazdutide cause?

Mazdutide's dominant side effects are nausea, vomiting, diarrhea, and decreased appetite, which are dose-dependent and track the incretin class overall.

A resting heart-rate increase is a possible signal specifically associated with glucagon receptor agonism, one that GLP-1-only and GLP-1/GIP drugs do not carry in the same way. Trial safety monitoring has tracked it as part of this drug class. Gallbladder and pancreatitis risks appear as standard incretin-class monitoring items, not as unique mazdutide findings. A practical guide to using GLP-1 medications well covers the incretin class more broadly.

Is mazdutide approved outside China?

Mazdutide is approved only in China, as Xinermei, and remains investigational everywhere else.

Gray-market "research peptide" vials carry no verified identity, purity, or potency. That sourcing risk sits outside the clinical trial supply chain and exists independent of anything the RCTs demonstrate about the molecule itself.

What is still unknown about mazdutide?

Long-term cardiovascular safety and efficacy outside Chinese populations are the biggest open questions about mazdutide:

• Durability. No published trial has run past 48 weeks, so the durability of weight loss and long-term glycemic effects are unanswered.
• Heart rate. Whether the resting heart-rate signal grows or stabilizes with chronic use is unknown.
• Other populations. Every trial enrolled Chinese participants exclusively. No published data show how mazdutide performs across different baseline metabolic profiles, body compositions, and concurrent medication patterns outside that population.
• Cardiovascular outcomes. No hard cardiovascular outcome trial of mazdutide exists yet.